Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Pilot Program for Japan-Version “Compassionate Use” System to Begin at National Cancer Center
July 23, 2013
-
REGULATORY 1st Committee to Discuss Approval of New Products Including Janssen’s Extended Release Schizophrenia Treatment
July 23, 2013
-
REGULATORY MHLW Mulls “Ultra-Orphan” Drug System; Designation Might Become Possible with Pre-Clinical, Healthy Subject Data
July 22, 2013
-
REGULATORY US Aims for Lifting of Ban on Mixed Care: Prof. Murakami of Yamagata University
July 22, 2013
-
ORGANIZATION FPMAJ Settles on Industry View for TPP, Demands Intellectual Property Protection on Par with Japanese Rules
July 19, 2013
-
REGULATORY South Korean MOHW Officials Announce Roadmap for South Korea to Become No. 7 Worldwide in New Drug Development by 2020
July 19, 2013
-
BUSINESS Pfizer Paid 23.9 Billion Yen to Physicians, Medical Institutions in FY2012; 1st Disclosure under JPMA Guidelines
July 18, 2013
-
ACADEMIA University’s Seriousness to Unravel Diovan Saga Called into Question
July 17, 2013
-
REGULATORY 2nd Committee on Drugs to Discuss Approval for Asthma Treatment Flutiform on July 26
July 17, 2013
-
REGULATORY MHLW, US FDA to Exchange Information with a View to Standardizing Review Guidelines for Regenerative Medicines
July 17, 2013
-
REGULATORY Health Ministry to Set Up Committee on Diovan Studies, Compile Preventive Measures for Clinical Data Manipulation
July 16, 2013
-
REGULATORY MHLW Presses Kyoto Prefectural University of Medicine to Carry on Diovan Probe
July 16, 2013
-
ACADEMIA “Data Manipulated” in KYOTO Heart Study: Univ. Probe
July 12, 2013
-
ORGANIZATION JPWA Sets Up New Committee on Consumption Tax, NHI Drug Pricing Issues
July 12, 2013
-
BUSINESS Drug Makers to Disclose Payment Information This Summer Based on Transparency Guidelines
July 11, 2013
-
BUSINESS Blood Derivative Titan CSL Set to Beef Up Japan Biz with New Products
July 10, 2013
-
REGULATORY TPP Member States to Brief Japan on Drug Pricing, Intellectual Property on July 25
July 9, 2013
-
ORGANIZATION JSGM Officially Announces Unified Brand Name Plan for Generic Combination Drugs; 1st Single Name to Be Given to Preminent
July 8, 2013
-
ORGANIZATION JSGM Working to Build Consensus on Unified Brand Names for Generic Combination Drugs
July 5, 2013
-
ACADEMIA “No Data Manipulation” in VART Study of Diovan: Interim Report of Japanese Society of Hypertension
July 4, 2013
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…